AlphaQuest LLC Buys 17,523 Shares of Supernus Pharmaceuticals, Inc. $SUPN

AlphaQuest LLC raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 360.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,391 shares of the specialty pharmaceutical company’s stock after buying an additional 17,523 shares during the period. AlphaQuest LLC’s holdings in Supernus Pharmaceuticals were worth $706,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SUPN. Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $46,000. GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 1,541 shares in the last quarter. CWM LLC raised its holdings in Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 1,479 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $103,000.

Supernus Pharmaceuticals Stock Down 0.2%

Shares of SUPN opened at $52.72 on Tuesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $54.79. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of 45.84 and a beta of 0.78. The stock’s 50-day moving average price is $47.07 and its 200 day moving average price is $38.16.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. TD Cowen raised their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Insider Transactions at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 14,000 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jack A. Khattar sold 140,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares in the company, valued at $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 362,741 shares of company stock valued at $16,390,592. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.